Advertisement

Advertisement
Lung Cancer

ADRIATIC Trial: Durvalumab Consolidation Extends Survival in Limited-Stage Small Cell Lung Cancer

Consolidation therapy with the PD-1 immune checkpoint inhibitor durvalumab is set to become the new global standard of care for patients with limited-stage small cell lung cancer (SCLC), according to groundbreaking data presented at the European Society for Medical Oncology (ESMO) Congress 2024. These findings from the phase III ADRIATIC trial represent the first major progress in the treatment of limited-stage SCLC in nearly 40 years.


Issues in Oncology

Tumor Treating Fields Therapy Receives FDA Approval in Metastatic NSCLC

Yesterday, Novocure announced the U.S. Food and Drug Administration (FDA) approval of Optune Lua for concurrent use with PD-1/PD-L1 inhibitors or docetaxel for the treatment of adults with metastatic non–small cell lung cancer (NSCLC) who have experienced disease progression on or after a platinum-based regimen. This wearable treatment device delivers tumor treating fields, which exert physical forces on the electrically charged components of dividing cancer cells, resulting in cell death.

 

Lung Cancer

Addition of Ramucirumab to Osimertinib in TKI-Naive EGFR-Mutant Metastatic NSCLC

In an interim analysis of the phase II RAMOSE trial, reported in the Journal of Clinical Oncology, Le et al found that the addition of ramucirumab to osimertinib significantly prolonged progression-free survival as initial treatment in patients with tyrosine kinase inhibitor (TKI)-naive EGFR-mutant metastatic non–small cell lung cancer (NSCLC).


Advertisement
Bladder Cancer

Standard vs Extended Lymphadenectomy in Radical Cystectomy for Muscle-Invasive Bladder Cancer

As reported in The New England Journal of Medicine by Lerner et al, the phase III SWOG S1011 trial showed no disease-free survival benefit for extended vs standard lymphadenectomy in patients with muscle-invasive bladder cancer undergoing radical cystectomy.

 

Issues in Oncology

Head and Neck Cancer Clinical Trials May Be Becoming Less Diverse, Despite National Efforts

Many patients with head and neck cancer may lack equal opportunity to access experimental treatments in clinical trials or receive treatments that were shown to be effective in similar patients, according to a recent study published by Zuckerman and Edwards in Head & Neck.

Advertisement
Advertisement




Sponsored Content

More Top Stories


Hematologic Malignancies

Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease

Global Cancer Care

Shared Reflections on the 2024 ASCO Annual Meeting: From Networking to Mentorship and More

The ASCO Annual Meeting brings together oncologists, researchers, and health-care professionals to share the latest advancements in cancer care. The 2024 ASCO Annual Meeting (ASCO24) was particularly momentous for those of who received the international development and education award (IDEA). As...

Advertisement

Large Proportion of Childhood Cancer Survivors May Experience Significant Fear of Cancer Recurrence

Investigators have found that one-third of adult survivors of childhood cancers may experience a severe fear of cancer recurrence that impacts their daily lives, according to a recent study published by Pizzo et al in JAMA Network Open. Background Although the number of survivors of childhood...

Paolo Corradini, MD, on PMBCL and DLBCL: Comparing Outcomes With Axicabtagene Ciloleucel

Legislation

Cancer Provider Groups Across the Country Urge Congress to Pass Prior Authorization Reform

The Association for Clinical Oncology (ASCO), along with 46 state oncology societies, sent a letter to U.S. House and Senate leadership urging Congress to pass the Improving Seniors’ Timely Access to Care Act (H.R. 8702/S. 4532), which would streamline prior authorization practices within Medicare...

Genomics/Genetics

Coping With the Risk of Hereditary Cancer

All these preventive strategies to avoid cancer or to catch it early have made me feel both in control and out of control of my health. — Frances Merrill Tweet this quote Three years ago, it had become clear that I needed to be tested for the BRCA1/2 mutation. I knew...

New Data From SWOG S1826 Trial May Confirm Benefit of Nivolumab Plus AVD in Patients With Hodgkin Lymphoma

Researchers have found that the combination of nivolumab plus doxorubicin, vinblastine, and dacarbazine (AVD) may reduce the risk of cancer progression and mortality in patients with Hodgkin lymphoma compared with standard treatment, according to a recent study published by Herrera et al in The New ...

Hematologic Malignancies
Leukemia

Nigel Russell, MD, on Acute Myeloid Leukemia: New Findings on FLAG-Ida and Gemtuzumab Ozogamicin

Ann Partridge, MD, MPH, Receives ESMO Award for Significant Contributions to Breast Cancer Research and Patient Care

Ann Partridge, MD, MPH Ann Partridge, MD, MPH, of Dana-Farber Cancer Institute, was named the recipient of the 2024 ESMO Award during the opening session of the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona. The international award recognizes her work and commitment...

Advertisement

Association of TERT Expression and Survival in Pulmonary Carcinoids

As reported in the Journal of Clinical Oncology by Werr et al, high telomerase reverse transcriptase (TERT) expression has been found to be associated with poorer survival in patients with pulmonary carcinoids. As stated by the investigators: “The clinical course of pulmonary carcinoids ranges from ...

ASCO Post X Feed
Social Media Hub by Everwall